Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Dr Vanessa Yardley

Assistant Professor

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
+44 (0)207 927 2462
Jump to: Affiliations Teaching Research Publications

A member of staff and a student at LSHTM since the early 1990's, working in a kinetoplastid drug discovery group. Collaborating with over 100 stakeholders during this time, across academia and Pharma, to identify new therapies for NTDS and malaria.

Affiliations
Department of Infection Biology
Faculty of Infectious and Tropical Diseases

Centres

Antimicrobial Resistance Centre

Teaching

Module Organiser for core module in Parasitology & Entomology for MSc students.

Contributing lecturer, kinetoplastid and NTD chemotherapy, on other MSc modules.

Co-organiser of MSc Field Trip (1 week)

Lead educator and developer of KalalCORE MOOC ( Control & Treatment of Visceral Leishmaniasis)

Research

Drug discovery and development

In vitro and in vivo models of infection to identify novel compounds and regimens to treat kinetoplastid infections. Use of PK PD sampling to inform drug activity in models and development of techniques to better predict outcomes in human infection.

Research Area
Chemotherapy
Complex interventions
Diagnostics
Drug discovery and development
Drug resistance
Pharmacokinetics
Protozoa
Trypanosomes
Cell biology
Immunopathology
Parasitology
Pathology
Pharmacology
Disease and Health Conditions
African trypanosomiasis
Chagas Disease
Leishmaniasis
Malaria
Neglected Tropical Diseases (NTDs)
Infectious diseases
Emerging infectious diseases
Skin diseases
Country
Afghanistan
Australia
Bangladesh
Belgium
Brazil
Colombia
Ethiopia
France
Germany
India
Iran
Japan
Nepal
New Zealand
Pakistan
South Sudan
Sudan
Syrian Arab Republic
Tunisia
United Kingdom
Region
Latin America & Caribbean (all income levels)
Sub-Saharan Africa (all income levels)

Selected Publications
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.
Braillard, S; Keenan, M; Breese, KJ; Heppell, J; Abbott, M; Islam, R; Shackleford, DM; Katneni, K; Crighton, E; Chen, G; Patil, R; Lee, G; White, KL; Carvalho, S; WALL, RJ; Chemi, G; Zuccotto, F; González, S; Marco, M; Deakyne, J; Standing, D; Brunori, G; Lyon, JJ; Castañeda-Casado, P; Camino, I; ... Chatelain, E.
2023
Science translational medicine
Protocol for a prospective observational cohort study of cutaneous leishmaniasis in Ethiopia
Mohammed, AB; Mohammed, FD; Zewdu, FT; Nigusse, SD; Hailemichael, Y; Cherkose, T; Alemu, AY; Molla, E; Bobosha, K; YARDLEY, V; Mosweu, I; Kaba, M; PITT, C; Allen, E; LAMBERT, SM; MARKS, M; WALKER, S; Gadisa, E; SHARP collaboration,;
2023
NIHR Open Res
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Van Bocxlaer, K; Dixon, J; Platteeuw, JJ; Van Den Heuvel, D; Mcarthur, K-N; Harris, A; Alavijeh, M; Croft, SL; YARDLEY, V;
2023
The Journal of antimicrobial chemotherapy
Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities
Basilico, N; Parapini, S; D'Alessandro, S; Misiano, P; Romeo, S; Dondio, G; YARDLEY, V; Vivas, L; Nasser, S; Rénia, L; Russell, BM; Suwanarusk, R; Nosten, F; Sparatore, A; Taramelli, D;
2023
Biomolecules
Artemisinin Cocrystals for Bioavailability Enhancement. Part 2: In Vivo Bioavailability and Physiologically Based Pharmacokinetic Modeling.
Kaur, M; YARDLEY, V; Wang, K; Masania, J; Arroo, RR J; Turner, DB; Li, M;
2021
MOLECULAR PHARMACEUTICS
Artemisinin Cocrystals for Bioavailability Enhancement. Part 1: Formulation Design and Role of the Polymeric Excipient.
Kaur, M; YARDLEY, V; Wang, K; Masania, J; Botana, A; Arroo, RR J; Li, M;
2021
MOLECULAR PHARMACEUTICS
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis
Mowbray, CE; Braillard, S; Glossop, PA; Whitlock, GA; Jacobs, RT; Speake, J; Pandi, B; Nare, B; Maes, L; YARDLEY, V; Freund, Y; Wall, RJ; Carvalho, S; Bello, D; Van den Kerkhof, M; Caljon, G; Gilbert, IH; Corpas-Lopez, V; Lukac, I; Patterson, S; Zuccotto, F; Wyllie, S;
2021
ACS Publications
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Mowbray, CE; Braillard, S; Glossop, PA; Whitlock, GA; Jacobs, RT; Speake, J; Pandi, B; Nare, B; Maes, L; YARDLEY, V; Freund, Y; WALL, RJ; Carvalho, S; Bello, D; Van den Kerkhof, M; Caljon, G; Gilbert, IH; Corpas-Lopez, V; Lukac, I; Patterson, S; Zuccotto, F; Wyllie, S;
2021
Journal of Medicinal Chemistry
Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.
Sanderson, L; Da Silva, M; Sekhar, GN; Brown, RC; Burrell-Saward, H; Fidanboylu, M; Liu, B; Dailey, LA; Dreiss, CA; Lorenz, C; Christie, M; Persaud, SJ; YARDLEY, V; CROFT, SL; Valero, M; Thomas, SA;
2021
PLoS neglected tropical diseases
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.
Thompson, AM; O'Connor, PD; YARDLEY, V; Maes, L; Launay, D; Braillard, S; Chatelain, E; Wan, B; Franzblau, SG; Ma, Z; Cooper, CB; Denny, WA;
2021
ACS medicinal chemistry letters
See more information
Vanessa Yardley

Contact

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
+44 (0)207 927 2462